Immunomedics In Software Project With Ideagen To Streamline Document Reviews Of Cancer Treatment Processes

Ideagen’s PleaseReview will improve review, co-authoring and redaction projects linked to cancer and other oncology treatments

US-based pharmaceutical company, Immunomedics, is to work with Ideagen in a software project designed to enhance processes associated with cancer and other oncology treatments.

Immunomedics will implement Ideagen’s PleaseReview product to improve its regulatory and process-driven documentation review projects.

More than 300 Immunomedics’ staff are involved in the creation, review, co-authoring and redaction processes of critical documentation linked to oncology treatments, specifically cancers.

Now review projects – which can involve anything up to 50 authors and reviewers at any one time – will be managed centrally and electronically via Ideagen’s software.

Kiyoung Hong, Director of Regulatory Operations and Publishing at Immunomedics, said: “PleaseReview will be an extremely beneficial system for us as we look to streamline and improve our entire document creation and review processes.

“These projects can be quite intense and time-consuming, with sometimes up to 50 authors and reviewers involved at any one time.

“PleaseReview will significantly simplify this process, reducing overall review times and making it easier and quicker for often crucial pieces of documentation to be completed and signed off.”

Focussing on the development of antibody-drug conjugates for the treatment of cancers, Immunomedics create and review several types of documentation as part of their day-to-day work. These include;

  • Regulatory
  • Clinical
  • Chemistry, Manufacturing and Controls (CMC) Regulatory Affairs

Mr. Hong added: “Initially, PleaseReview will be used for our regulatory submission documents but over time it will be our system for organisation-wide document reviews.”

Martin Joynes, Ideagen’s Product Manager for PleaseReview, said: “This is a fantastic project for Ideagen. We are excited to be working with such a large, ambitious and growing pharmaceutical company in the form of Immunomedics.

“This is yet another outstanding testament to the capabilities of our PleaseReview software. It is gratifying that PleaseReview is contributing to the vision of creating and delivering breakthrough therapies for hard to treat cancers, transforming patients’ lives.

“We are delighted to welcome Immunomedics to the Ideagen community.”

PleaseReview is Ideagen’s document review, co-authoring and redaction software application that helps organisations control and manage all aspects of the document creation and review process.

The software is used by more than 300 clients globally.

www.ideagen.com
www.ideagen.com/products/pleasereview
www.immunomedics.com

Joe O’Brien
PR & Media Relations
Ideagen

+44 (0) 1629 699100
+44 (0) 7916 131501
joseph.obrien@ideagen.com

user

Recent Posts

Sonendo Strengthens Leadership With Key Strategic Appointments

John Bostjancic Appointed as Chief Financial Officer Bob Guyatt Appointed as Senior Vice President of…

5 hours ago

ACSD Granted Significant Telemedicine Patent

IRVINE, Calif., June 5, 2024 /PRNewswire/ -- ACS Diagnostics, Inc. of Irvine CA, with executive…

5 hours ago

Neogen® to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

LANSING, Mich., June 5, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG), an innovative leader in…

5 hours ago

Alleva Shines at the West Coast Symposium on Addictive Disorders

Leading Behavioral Health Practice Management Platform Showcases Innovation and Care at Premier Industry Event PALM…

5 hours ago

BRIJ Medical Launches Brijjit BP-75: Precision Technology for Smaller Surgical Incisions

MARIETTA, Ga., June 5, 2024 /PRNewswire/ -- BRIJ Medical, a medical device company revolutionizing surgical…

5 hours ago

Activated Insights Powers Majority of Award-Winning Communities in 2024 U.S. News Best Senior Living Ratings

REXBURG, Idaho, June 5, 2024 /PRNewswire/ -- Activated Insights, an HCP company, has played a pivotal…

5 hours ago